A Phase 2, Open-Label Study of the Safety and Efficacy of INCB040093 and INCB040093 Combined With INCB039110 in Subjects With Relapsed or Refractory Hodgkin Lymphoma

SUMMARY

N/A

COH Protocol Number : 15127

ClinicalTrials.gov Number : NCT02456675

Principal Investigator : Chen, Robert M.D.

Sponsor : Incyte Corporation

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Either

Minimum Performance Status : ECOG/SWOG:2

Treatment Intent : Non-Adjuvant treatment

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :